Clinical trials: Refractory Hematologic Malignancy
Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia
Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Determine the maximum tolerated dose (MTD) and toxicity profile of the combination of cyclophosphamide and ATO (Arsenic Trioxide) in subjects with relapsed refractory AML.
- Trial name
- NCT03318016
- Testing
- Cyclophosphamide 500 MG, Cyclophosphamide 1000 MG, Cyclophosphamide 2000 MG
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Colorado, Denver
CD22 Positive, Recurrent Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia
This phase II trial studies how well inotuzumab ozogamicin works in treating patients with CD22 positive acute lymphoblastic leukemia that has come back or does not respond to treatment.
- Conditions
- CD22 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT03094611
- Testing
- Inotuzumab Ozogamicin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
B-cell Malignancy, Non-Hodgkin Lymphoma
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.
- Conditions
- B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL
- Trial name
- NCT04035434
- Testing
- CTX110
- Where
- 33 sites in United States, Australia and 4 more
- Volunteers
- 93 people
- Sponsor
- CRISPR Therapeutics AG
Hematologic Neoplasms
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
The primary objectives of Phase 1 Dose Escalation/Part 1 Expansion are: To assess the safety and tolerability of treatment with enasidenib administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle…
- Trial name
- NCT01915498
- Testing
- Enasidenib
- Where
- 24 sites in United States, France
- Volunteers
- 345 people
- Sponsor
- Celgene
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies how well sonidegib and lenalidomide after stem cell transplant works in treating patients with multiple myeloma.
- Trial name
- NCT02086552
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Sonidegib
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
The primary objective of the study is to evaluate the safety of idelalisib in combination with an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, a mammalian target of rapamycin (mTOR) inhibitor, a protease…
- Conditions
- Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Trial name
- NCT01088048
- Testing
- Idelalisib, Rituximab, Bendamustine
- Where
- 11 sites in United States
- Volunteers
- 241 people
- Sponsor
- Gilead Sciences
Acute Myeloid Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from dividing.
- Conditions
- Acute Myeloid Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT00602225
- Testing
- clofarabine, cytarabine, filgrastim
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Acute Leukaemia, Chronic Disease
Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
This is a phase II trial of reduced intensity conditioning with Bu/Flu/ATG in pediatric patients with hematologic malignancies at high risk for transplant related mortality with standard transplantation.
- Conditions
- Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia
- Trial name
- NCT00795132
- Testing
- Busulfan, Anti-Thymocyte Globulin, Fludarabine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Utah
Multiple Myeloma
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of Part 1 of the study is to determine the safety of the combination of Siltuximab (CNTO 328) and bortezomib (Velcade).
- Trial name
- NCT00401843
- Testing
- Siltuximab, Bortezomib, Dexamethasone
- Where
- 80 sites in United States, Belgium and 16 more
- Volunteers
- 307 people
- Sponsor
- Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Background: B-cell leukemias and lymphomas are cancers that are often difficult to treat. The primary objective of this study is to determine the ability to take a patient's own cells (T lymphocytes) and grow them in the…
- Conditions
- Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma, B-Cell Leukemia
- Trial name
- NCT03448393
- Testing
- CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Refractory Multiple Myeloma
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
This is a single-center, non-randomized, phase 2 study in which patients will receive daratumumab (subcutaneous, SC) in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or…
- Conditions
- Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
- Trial name
- NCT04302324
- Testing
- Daratumumab SC, Clarithromycin, Pomalidomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Weill Medical College of Cornell University
Adult T Cell Leukemia, Adult T Cell Lymphoma
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
This clinical trial will be a multicenter phase II fixed-dose trial in which a minimum of 10 patients with immunophenotypically confirmed ATL with at least 50% of the blasts expressing CD25 as measured by flow cytometry at…
- Trial name
- NCT01378871
- Testing
- IMTOX-25
- Where
- 7 sites in United States
- Volunteers
- 1 people
- Sponsor
- Amit Verma
Multiple Myeloma
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
To explore whether Elotuzumab dose administration over approximately 60 minutes is feasible and safe.
- Trial name
- NCT02159365
- Testing
- Elotuzumab, Lenalidomide, Dexamethasone
- Where
- 29 sites in United States
- Volunteers
- 84 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma, Solid Tumors
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer.
- Conditions
- Multiple Myeloma, Solid Tumors, Non-Small Cell Lung Cancer
- Trial name
- NCT01457417
- Testing
- DKN-01
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Leap Therapeutics, Inc.
Multiple Myeloma and Plasma Cell Neoplasm
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00687674
- Testing
- dexamethasone, sorafenib tosylate, Lenalidomide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
Lymphoma
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A phase I dose escalation study of veltuzumab and milatuzumab in relapsed and refractory B-cell NHL. The phase I study will be followed by a pilot phase II study.
- Trial name
- NCT00989586
- Testing
- milatuzumab, veltuzumab, Correlative/Special Studies
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Beth Christian
Relapsed and Bortezomib Refractory Multiple Myeloma, Refractory Multiple Myeloma
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
This study is designed to assess the effectiveness of the combination of Panobinostat plus Bortezomib and Dexamethasone in patients with relapsed and bortezomib refractory Multiple Myeloma.
- Conditions
- Relapsed and Bortezomib Refractory Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse
- Trial name
- MACS1271 (NCT01083602)
- Testing
- panobinostat, bortezomib, dexamethasone
- Where
- 13 sites in United States
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Japanese participants with…
- Trial name
- DREAMM 7 (NCT06868667)
- Testing
- Belantamab mafodotin, Daratumumab, Bortezomib
- Where
- 16 sites in Japan
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
This phase II MATCH treatment trial identifies the effects of afatinib in patients whose cancer has genetic changes called HER2 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439136
- Testing
- Afatinib Dimaleate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Myelodysplastic Syndromes
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
RATIONALE: Vatalanib may be effective in preventing the development of leukemia in patients who have myelodysplastic syndromes. PURPOSE: This phase II trial is studying vatalanib to see how well it works in treating patients with…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00072475
- Testing
- vatalanib
- Where
- 68 sites in United States
- Volunteers
- 155 people
- Sponsor
- Alliance for Clinical Trials in Oncology